VIDEO: What clinical research tells us about sotagliflozin and heart failure

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, spoke with us about the role of sodium–glucose co-transporter-2 (SGLT2) inhibitors when treating heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. 

"The SGLT-2 inhibitors have played a major role in HF. The results from the SGLT2 inhibitors, especially the selective ones with empagliflozin and dapagliflozin, are really pretty sensational," Pitt said.